National Asset Management Inc. grew its holdings in shares of Sanofi SA (NYSE:SNY) by 5.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 10,666 shares of the company’s stock after purchasing an additional 537 shares during the period. National Asset Management Inc.’s holdings in Sanofi were worth $474,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the business. Bessemer Group Inc. lifted its position in Sanofi by 11.8% during the 4th quarter. Bessemer Group Inc. now owns 2,409 shares of the company’s stock worth $104,000 after buying an additional 255 shares in the last quarter. OLD National Bancorp IN lifted its position in Sanofi by 2.4% during the 1st quarter. OLD National Bancorp IN now owns 11,434 shares of the company’s stock worth $506,000 after buying an additional 271 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Sanofi by 11.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,772 shares of the company’s stock worth $123,000 after buying an additional 286 shares in the last quarter. Global Retirement Partners LLC lifted its position in Sanofi by 28.0% during the 1st quarter. Global Retirement Partners LLC now owns 1,331 shares of the company’s stock worth $59,000 after buying an additional 291 shares in the last quarter. Finally, Focused Wealth Management Inc lifted its position in Sanofi by 33.2% during the 4th quarter. Focused Wealth Management Inc now owns 1,204 shares of the company’s stock worth $52,000 after buying an additional 300 shares in the last quarter. 7.04% of the stock is currently owned by hedge funds and other institutional investors.
In other news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.00% of the stock is currently owned by corporate insiders.
Shares of SNY stock opened at $42.28 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $106.04 billion, a PE ratio of 13.51, a PEG ratio of 2.41 and a beta of 0.67. Sanofi SA has a 52-week low of $37.67 and a 52-week high of $45.62.
Sanofi (NYSE:SNY) last issued its earnings results on Friday, April 26th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.07. The company had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.34 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. Sanofi’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.28 EPS. As a group, equities analysts forecast that Sanofi SA will post 3.1 earnings per share for the current year.
The company also recently announced an annual dividend, which will be paid on Friday, May 31st. Stockholders of record on Wednesday, May 8th will be issued a $1.7395 dividend. The ex-dividend date is Tuesday, May 7th. This represents a dividend yield of 4.2%. Sanofi’s payout ratio is 37.38%.
COPYRIGHT VIOLATION WARNING: This news story was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/25/national-asset-management-inc-has-474000-holdings-in-sanofi-sa-sny.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: Short Selling Stocks, A Beginner’s Guide
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.